Rapid Micro Biosystems stock reports Q2 revenue growth 11 percent

Published on 10/05/2026 at 09:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Rapid Micro Biosystems stock reported USD 8.05 million in second-quarter revenue, above the USD 7.88 million consensus. Analysts list a USD 5.00 average target.

RPID, US75340L1044, Illustration mit AI erstellt.

Rapid Micro Biosystems stock (ISIN US75340L1044) closed at USD 0.92 on Nasdaq on October 2, 2026, while the company reported second-quarter revenue of USD 8.1 million and an 11 percent year-over-year increase. The result keeps the company focused on scaling its Growth Direct automation platform as losses remain central to the investment case.

Revenue beats while losses widen

Rapid Micro Biosystems reported second-quarter 2026 total revenue of USD 8.1 million, representing 11 percent growth from the second quarter of 2025, according to Rapid Micro Biosystems. The company also said it placed four Growth Direct systems and completed nine validations during the quarter, bringing global placements to 200.

The detailed quarterly figures show revenue of USD 8.05 million for Q2/2026, above the USD 7.88 million consensus. The reported loss was USD 0.27 per share, USD 0.03 worse than the USD 0.24 consensus loss, according to MarketBeat. That split between top-line growth and per-share losses makes margin expansion the key operating question.

Automation platform reaches 200 systems

The Growth Direct platform automates microbial quality-control testing for pharmaceutical, biologics, medical-device and personal-care production. The company describes the system as a way to replace manual workflows with faster testing, software connectivity and recurring consumables and services.

Rapid Micro Biosystems ended Q2/2026 with USD 14.687 million in cash and used USD 12.702 million in operating cash flow during the period. Its second-quarter gross margin was 15 percent, compared with 5 percent in the first quarter of 2026, a sequential improvement of 10 percentage points that provides a concrete measure of the scaling challenge.

Analysts see a wide valuation gap

MarketBeat reports a Moderate Buy consensus from four analysts and an average price target of USD 5.00. Roth Capital upgraded the stock to Strong Buy, while Weiss Ratings maintained a Sell rating, leaving the published views divided despite the positive consensus label.

The average target stands USD 4.08 above the October 2 closing price, a difference of 443.5 percent relative to the share price. The comparison is substantial, but the Q2 loss and operating cash use show why the market continues to value execution and financing risk alongside the company growth narrative.

Stock stays near its yearly low

Rapid Micro Biosystems closed at USD 0.92 on Nasdaq on October 2, 2026, with a market capitalization of USD 41.7 million and a 52-week range of USD 0.86 to USD 4.94. Volume was 329,276 shares, giving the stock a dated market anchor while the company works toward broader system adoption.